Updated:
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics develops investigational oncolytic-virus technologies, including its RedTail platform and CLD-401 candidate.
Overview
Calidi Biotherapeutics develops investigational oncology technologies using engineered oncolytic viruses. Its RedTail platform is designed to deliver genetic medicines to tumor sites, with CLD-401 identified as its first candidate from that platform. These development aims do not establish regulatory approval or demonstrated patient benefit. The company reported an offering closing on September 21, 2026. A separate September equity-compliance notice set an October 21 deadline for submitting a compliance plan. Its reported principal executive office is in San Diego, CA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included a net loss of USD 19,906,000; cash used in operations of USD 21,293,000. At that year-end, it reported total assets of USD 8,857,000. Historical figures retain the originally filed amounts where later comparative figures differ.
Company overview
- Legal name
- Calidi Biotherapeutics, Inc.
- Former names in filing history
- Calidi Biotherapeutics, Inc. (2023-09-25 to 2026-09-25); First Light Acquisition Group, Inc. (2021-05-17 to 2023-09-19)
- Classification
- Public company
- Industry (SIC)
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001855485
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|
| FY2025USD | -$19.9M | $8.9M | — | -$21.3M | |
| FY2024USD | -$22.1M | $14.2M | $9.6M | -$19.7M | |
| FY2023USD | -$29.2M | $10.0M | — | -$27.0M | |
| FY2022USD | $3.5M | $42.9M | — | $98,051 |
FY2022. Net income, Total assets, Operating cash flow: shown as originally filed; later filings report different values for the same periods.
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Calidi Biotherapeutics, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.